Navigation Links
Leading Proxy Advisory Firm RiskMetrics Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group
Date:3/5/2009

Urges LCA-Vision Stockholders to Vote the GOLD Card

CINCINNATI, March 5 /PRNewswire-FirstCall/ -- LCA-Vision Inc. (Nasdaq: LCAV) announces that RiskMetrics Group's ISS Governance Services has recommended that LCA-Vision stockholders vote to retain the Company's current Board of Directors and reject all proposals, including the removal of the current Directors and election of replacement Directors, in the Joffe Group's consent solicitation. After in-person meetings with LCA-Vision Board and management representatives as well as with the dissident group, and conducting a thorough analysis of their proposals and supporting statements, RiskMetrics recommends that LCA-Vision stockholders vote in support of the Board and management on all proposals.

RiskMetrics Group is a leading proxy advisory firm, and its analyses and recommendations are relied upon by many of the world's leading institutional investors.

"In evaluating the questions of whether change in management at LCA-Vision is warranted and whether stockholders might be better served by the dissidents' proposals, RiskMetrics responded with a clear and convincing 'no' to both," said Steven Straus, LCA-Vision chief executive officer. "Current management and the Board of Directors are working diligently to build stockholder value. We have undertaken a multi-initiative plan that encompasses all aspects of our business and are delighted that RiskMetrics recognizes our actions and accomplishments. We urge our stockholders to follow the recommendations of RiskMetrics and last week's recommendations by Glass Lewis in voting for our current Board and in support of the current management team."

In its report dated March 4, 2009, RiskMetrics states, among other things:

  • Under the leadership of CEO Steve Straus, LCA's current management has responded to challenging economic conditions with a strategy "meant to position LCA to weather a sustained period of declining procedure volume."
  • RiskMetrics also recognizes LCA's performance improvements in recent quarters, including a gain in market share during the fourth quarter of 2008.
  • Regarding Stephen Joffe, the report states, "...we have governance concerns that preclude us from recommending support for him," and added, "We note that none of the other dissident [Board of Director] nominees have relevant company or industry specific experience."

Due to the nature of the Consent process, your voting instruction is extremely important and time sensitive. LCA-Vision urges all stockholders to vote their GOLD cards to REVOKE CONSENT on all three proposals. Please discard any proxy card that you receive from the Joffe Group. If you have already voted to consent and wish to change your vote, you have every right to revoke your consent and vote the GOLD proxy. Only the latest dated card counts.

LCA-Vision filed its Definitive Consent Revocation Statement ("Consent Revocation Statement") with the Securities and Exchange Commission on Monday, February 9, 2009, and copies of the Consent Revocation Statement with a GOLD Consent Revocation Card were mailed to stockholders beginning February 10, 2009. The Consent Revocation Statement can be obtained immediately from the SEC's website at the following link:

http://tinyurl.com/ce63la

or from the Investor Relations section of the Company's website at www.lasikplus.com and www.lca-vision.com. Copies of the Consent Revocation Statement and consent revocation card may also be obtained from Georgeson Inc.

Additional Information:

Georgeson Inc. has been retained by LCA-Vision as consent revocation solicitation agent. Stockholders with questions are encouraged to call Georgeson toll-free 1-800-457-0109. Copies of the Company's Consent Revocation Statement, and any other documents filed by LCA-Vision with the SEC in connection with the consent solicitation can be obtained free of charge from the SEC's website at www.sec.gov, from the Company's website at www.lasikplus.com and www.lca-vision.com, or from Georgeson.

About LCA-Vision Inc./LasikPlus(R)

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus(R) brand, operates 75 LasikPlus(R) fixed-site laser vision correction centers in 32 states and 57 markets in the United States and a joint venture in Canada. Additional company information is available at www.lca-vision.com and www.lasikplus.com.

Earning Trust Every Moment.

Transforming Lives Every Day.

    For Additional Information

    Company Contact:                     Investor Relations Contact:
    Barb Kise                            Jody Cain
    LCA-Vision Inc.                      Lippert/Heilshorn & Associates
    513-792-9292                         310-691-7100


'/>"/>
SOURCE LCA-Vision Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Naturally Safe Zucol(TM) Brings Europes Leading Cold Remedy to United States
2. NHPCO Comments on Misleading Quote in Associated Press Article and Provides Helpful Information
3. Global Med Technologies(R), Inc. Places Its Leading Edge Laboratory Information System at the Fontainebleau Hospital
4. Follow-Up Tests of Leading Personal Care and Household Cleaning Brands Reveal Significant Improvements in Levels of Carcinogenic 1,4-dioxane
5. GE Healthcare Extends Leading Web-Based Imaging Solutions to Asia
6. Leading Cause of Stress to Military War Veterans Key Topic at 35th Advanced International Winter Symposium
7. Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
8. Babylon Ltd., the International Leading Provider of Translation and Dictionary Software Company, Ranks No. 1 and Took the "TopTenREVIEWS Gold Award"
9. Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed
10. Elpac Power System 150-Watt Commercial External Power Supply Features Industry-Leading Efficiency and Power Density
11. IOF joins ECCEO9 at leading international meeting in Athens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery ... Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic ... , Dr. Olson says the decision to support the pageant in an ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based ... however, are unsure how to move forward, given the need to sustain current ... forward tailored to an organization’s specific needs. , PYA Principal Martie Ross states, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: